Search for content, post, videos

Novo Nordisk and the University of Toronto announce joint investment

Lars Fruergaard Joergensen

The DKK 200 million investment will be used to establish the Novo Nordisk Network for Healthy Populations.

The network will focus on new ways to support healthier urban populations and will draw on U of T’s expertise in public health research and education programmes to impact the global fight against diabetes and other serious chronic diseases, states Novo Nordisk in its press release. Based at U of T Mississauga, the new network will be a partnership between the Dalla Lana School of Public Health, the Temerty Faculty of Medicine and University of Toronto Mississauga.

“Fulfilling our company’s purpose to defeat diabetes, obesity and other serious chronic diseases requires much more than innovative medicine,” says Lars Fruergaard Jørgensen, CEO and President of Novo Nordisk. “One hundred years after the discovery of insulin, we’re proud to once again partner with the University of Toronto with the ambition of helping society to address the root causes of type 2 diabetes and obesity. As we recognize insulin’s success in saving millions of lives around the world, we are excited to expand our commitment towards the prevention of these serious chronic diseases.”

A historic investment

In 1921, a U of T research team of Frederick Banting, Charles Best, J.J.R. MacLeod and James Bertram Collip discovered insulin. Novo Nordisk predecessors, Nordisk Insulin Laboratorium and Novo Terapeutisk Laboratorium, were among the first to produce insulin at a large scale, bringing this life-saving treatment from University of Toronto labs to people with diabetes around the world. Now, 100 years later, U of T and Novo Nordisk will once again work together to improve the lives of people living with diabetes – with an ambition to prevent type 2 disease, states Novo Nordisk in its press release.

Novo Nordisk’s is donating DKK 100 million (CAD 20 million) to the network which is being matched by U of T with further DKK 100 million in financial and in-kind contributions. In addition, Novo Nordisk has made an additional DKK 10 million (CAD 2 million) donation to U of T’s Banting and Best Diabetes Centre in support of discovery research and to honor Banting and Best’s enduring legacy.

Photo of Lars Fruergaard Jørgensen, CEO and President of Novo Nordisk